Gemcitabine followed by radiotherapy in treatment of newly diagnosed high-grade gliomas

Abstract

Aim: High-grade glioblastoma multiforme (GBM) has a poor median overall survival (OS). The standard treatment after surgery is temozolomide and radiotherapy (RTH). Patients with unmethylated methylguanine-methyltransferase promoter (MGMT) have no or little benefit from temozolomide and are eligible for alternative therapies. Gemcitabine is a good radiosensitizer. We aimed to evaluate the combination of gemcitabine with RTH in newly diagnosed GBM. Methods: The study was a prospective phase II study. Eligible patients were required to have histologically proven anaplastic astrocytoma or GBM. Patients underwent biopsies or subtotal resection. The treatment consisted of fixed-dose rate gemcitabine 175 mg/m² weekly followed after 24 h by standard cranial RTH for 6 weeks. Tumor response was evaluated by Macdonald criteria. In case of progression, patients received temozolomide (200 mg/m²/5 days every 28 days). Results: Thirty patients with a median age of 52 years (30-69), 73%/27% male/female, the Eastern Cooperative Oncology Group performance status 1 (range 0-2) were enrolled. Five patients had a partial-response (17%) and 13 stable-disease (43%). Median time to progression was 7.88 months (95% CI 6.1-9.69) and OS was 11.77 months (95% CI 9.97-13.56). The treatment was well tolerated with grade-3 neutropenia in 3, grade-3 anemia in 2 and impaired liver enzymes in 1 patient. Conclusion: Gemcitabine followed by radiotherapy is active and promising regimen in newly diagnosed GBM. Gemcitabine uptake is easy, with a long local retention of active metabolites, precluding systemic side effects of radiosensitization. In a phase III study this treatment should be evaluated in patients with unmethylated MGMT promoter who will not benefit from temozolomide.

Keywords

Gemcitabine / radiation / glioblastoma multiforma / temozolomide

References

[1] Laperriere N,Zuraw L.Radiotherapy for newly diagnosed malignant glioma in adults..Toronto (ON): Cancer Care Ontario; 2005 Nov 2 [In review 2011 Sep]Program in Evidence-based Care Evidence-based Series No.: 9-3.

[2] Stupp R,van den Bent MJ,Fisher B,Belanger K,Marosi C,Curschmann J,Ludwin SK,Allgeier A,Cairncross JG,Mirimanoff RO.Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma..N Engl J Med2005;352:987-96

[3] Stupp R,Mason WP,Taphoorn MJ,Ludwin SK,Fisher B,Hau P,Gijtenbeek J,Vecht CJ,Wesseling P,Eisenhauer E,Weller M,Cairncross JG.Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial..Lancet Oncol2009;10:459-66

[4] Philip-Ephraim EE,Williams UE.The role of radiotherapy and chemotherapy in the treatment of primary adult high grade gliomas: assessment of patients for these treatment approaches and the common immediate side effects..ISRN Oncol2012;2012:902178

[5] Mathieu D.The role of chemotherapy in the treatment of malignant astrocytomas..Can J Neurol Sci2006;33:127-40

[6] Hegi ME,Gorlia T,de Tribolet N,Kros JM,Mason W,Bromberg JE,Mirimanoff RO,Janzer RC.MGMT gene silencing and benefit from temozolomide in glioblastoma..N Engl J Med2005;352:997-1003

[7] van Nifterik KA,Stalpers LJ,Leenstra S,Hulsebos TJ.Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines..Int J Radiat Oncol Biol Phys2007;69:1246-53

[8] Shewach DS.Gemcitabine and radiosensitization in human tumor cells..Invest New Drugs1996;14:257-63

[9] Shewach DS.Nucleoside radiosensitizers.. In: Cancer drug discovery and development entitled Deoxynucleoside analogues in cancer therapy, edited by GJ Peters, Humana press,2006;289-330[chapter 13].

[10] Shewach DS.Antimetabolite radiosensitizers..J Clin Oncol2007;25:4043-50

[11] Pastor-Anglada M,Errasti-Murugarren E.SLC28 genes and concentrative nucleoside transporter (CNT) proteins..Xenobiotica2008;38:972-94

[12] Heinemann V,Grindey GB.Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine..Cancer Res1988;48:4024-31

[13] Bergman AM,Peters GJ.Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine)..Drug Resist Updat2002;5:19-33

[14] Mini E,Caciagli B,Mazzei T.Cellular pharmacology of gemcitabine..Ann Oncol 2006;17 Suppl 5v7-12

[15] Elnaggar M,Peters GJ.Molecular targets of gemcitabine action: rationale for development of novel drugs and drug combinations..Curr Pharm Des2012;18:2811-29

[16] Tempero M,Ruiz Van Haperen V,Hochster H,Abbruzzese J.Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma..J Clin Oncol2003;21:3402-8

[17] Peters GJ,Noordhuis P,Laan AC,Edzes HT.Clinical phase I and pharmacology study of gemcitabine (2', 2'-difluorodeoxycytidine) administered in a two-weekly schedule..J Chemother2007;19:212-21

[18] Vernejoul F,Souque A,Drocourt D,Pradayrol L,Buscail L.Gene therapy based on gemcitabine chemosensitization suppresses pancreatic tumor growth..Mol Ther2006;14:758-67

[19] Ruiz van Haperen VW,Boven E,Vermorken JB.Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours..Biochem Pharmacol1994;48:1327-39

[20] Veerman G,Vermorken JB,Braakhuis BJM,Peters GJ.Antitumor activity of prolonged as compared with bolus administration of 2',2'-difluorodeoxycytidine in vivo against murine colon tumors..Cancer Chemother Pharmacol1996;38:335-42

[21] Abbruzzese JL.New applications of gemcitabine and future directions in the management of pancreatic cancer..Cancer2002;95:941-5

[22] Poplin E,Berlin J,Hochster H,Alberts S,Haller D,Cella D.Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group..J Clin Oncol2009;27:3778-85 PMCID:PMC2727286

[23] Gertler SZ,Goodyear M,Stewart DJ,Perry J,Steward W,Seymour L.NCIC-CTG phase II study of gemcitabine in patients with malignant glioma. (IND.94)..Ann Oncol2000;11:315-8

[24] Weller M,Wick W,Heiss E,Meyermann R,Bamberg M.Preirradiation gemcitabine chemotherapy for newly diagnosed glioblastoma. A phase II study..Cancer2001;91:423-7

[25] Ostruszka LJ.The role of cell cycle progression in radiosensitization by 2',2'-difluoro-2'-deoxycytidine..Cancer Res2000;60:6080-8

[26] Genç M,Barten-van Rijbroek A,Haveman J.Enhancement of effects of irradiation by gemcitabine in a glioblastoma cell line and cell line spheroids..J Cancer Res Clin Oncol2004;130:45-51

[27] Fehlauer F,Smid EJ,Richter E,Sminia P.Combined modality therapy of gemcitabine and irradiation on human glioma spheroids derived from cell lines and biopsy tissue..Oncol Rep2006;15:97-105

[28] Galbán S,Williams TM,Heist KA,Leopold JS,Lawrence TS,Mikkelsen T,Galbán CJ.DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma..PLoS One2012;7:e35857

[29] Sigmond J,Postma TJ,de Lange SM,Laan AC,Van Groeningen CJ,Giaccone G.Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer..Ann Oncol2009;20:182-7

[30] Metro G,Mirri MA,Pace A,Russillo M,Giannarelli D,Pompili A,Carapella CM.Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme..Cancer Chemother Pharmacol2010;65:391-7

[31] Kim MM,Cao Y,Marnmoser A,Sagher O,Tsien C.A phase I dose-escalation study of gemcitabine plus standard radiation therapy for malignant high grade gliomas..Int J Radiat Oncol Biol Phys2014;90:S282

[32] Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available at: http://ctep.cancer.gov (Last Accessed 1 July 2009).

[33] Macdonald DR,Schold SCJr.Response criteria for phase II studies of supratentorial malignant glioma..J Clin Oncol1990;8:1277-80

[34] Beauchesne PD,Bernier V.Concurrent radiotherapy: fotemustine combination for newly diagnosed malignant glioma patients, a phase II study..Cancer Chemother Pharmacol2009;64:171-5

[35] Athanassiou H,Maragoudakis E,Verigos C,Antonadou D,Beroukas K.Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme..J Clin Oncol2005;23:2372-7

[36] Rekers NH,Peters GJ.Towards tailored therapy of glioblastoma multiforme..J Chemother2011;23:187-99

[37] Peters GJ.Pyrimidine metabolism in rat brain cortex and liver..Adv Exp Med Biol1984;165:531-4

[38] van Putten JWG,Smid K,Kampinga HH.End-joining deficiency and radiosensitization induced by gemcitabine..Cancer Res2001;61:1585-91

[39] Pauwels B,Lardon F.Combined modality therapy of gemcitabine and radiation..Oncologist2005;10:34-51

[40] Pauwels B,Lambrechts HA,de Pooter CM,Vermorken JB.The radiosensitising effect of difluorodeoxyuridine, a metabolite of gemcitabine, in vitro..Cancer Chemother Pharmacol2006;58:219-28

[41] Wouters A,Burrows N,Deschoolmeester V,Laukens K,Van Gestel D,Van den Weyngaert D,Pauwels P,Lardon F.The radiosensitising effect of gemcitabine and its main metabolite dFdU under low oxygen conditions is in vitro not dependent on functional HIF-1 protein..BMC Cancer2014;14:594 PMCID:PMC4152599

[42] Honeywell RJ,Veerman G,Peters GJ.Inhibition of thymidylate synthase by 2΄,2΄-difluoro-2'-deoxycytidine (Gemcitabine) and its metabolite 2',2'-difluoro-2'-deoxyuridine..Int J Biochem Cell Biol2015;60:73-81